Guardant Health (GH) Expected to Announce Quarterly Earnings on Thursday

Guardant Health (NASDAQ:GH) will likely be posting its Q4 2025 results after the market closes on Thursday, February 19th. Analysts expect the company to announce earnings of ($0.43) per share and revenue of $269.7380 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 19, 2026 at 4:30 PM ET.

Guardant Health Trading Up 2.2%

NASDAQ GH opened at $107.11 on Wednesday. The firm has a market capitalization of $13.50 billion, a PE ratio of -33.37 and a beta of 1.63. The business’s 50-day moving average price is $106.47 and its two-hundred day moving average price is $85.23. Guardant Health has a 12 month low of $34.88 and a 12 month high of $120.74.

Insider Buying and Selling

In other Guardant Health news, CEO Amirali Talasaz sold 100,000 shares of the firm’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $105.05, for a total value of $10,505,000.00. Following the completion of the sale, the chief executive officer directly owned 168,223 shares in the company, valued at $17,671,826.15. This trade represents a 37.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Helmy Eltoukhy sold 90,565 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $103.82, for a total value of $9,402,458.30. Following the completion of the transaction, the chief executive officer owned 2,047,143 shares of the company’s stock, valued at approximately $212,534,386.26. The trade was a 4.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 434,511 shares of company stock valued at $45,580,887 over the last three months. Insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of GH. Alyeska Investment Group L.P. bought a new position in shares of Guardant Health during the 3rd quarter valued at $114,421,000. Price T Rowe Associates Inc. MD increased its position in Guardant Health by 33.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock valued at $575,670,000 after acquiring an additional 1,414,441 shares during the last quarter. Qube Research & Technologies Ltd increased its position in Guardant Health by 124.3% during the third quarter. Qube Research & Technologies Ltd now owns 570,095 shares of the company’s stock valued at $35,620,000 after acquiring an additional 315,896 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in Guardant Health by 205.6% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 464,905 shares of the company’s stock valued at $47,485,000 after acquiring an additional 312,783 shares during the period. Finally, Artisan Partners Limited Partnership purchased a new position in Guardant Health in the fourth quarter worth about $29,657,000. 92.60% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

GH has been the topic of several analyst reports. Canaccord Genuity Group upped their target price on Guardant Health from $100.00 to $125.00 and gave the company a “buy” rating in a report on Monday, December 22nd. JPMorgan Chase & Co. boosted their price target on shares of Guardant Health from $90.00 to $120.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Barclays upped their price objective on shares of Guardant Health from $85.00 to $120.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Robert W. Baird began coverage on shares of Guardant Health in a research note on Tuesday. They set an “outperform” rating and a $120.00 target price for the company. Finally, Wells Fargo & Company boosted their target price on shares of Guardant Health from $93.00 to $120.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Twenty-two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $107.45.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.